Plant-Based Drug Candidate for Diabetic Foot Ulcers

CSIR-Indian Institute of Chemical Technology (IICT) develops a plant-based drug candidate for diabetic foot ulcers under the ‘CSIR Phytopharmaceutical Mission Phase III’. The phytopharmaceutical is derived from Gymnema sylvestre, and the research has secured patent protection in India and international jurisdictions.

CSIR-IICT Plant-Based Drug Candidate:

Dimension	Key Details
Reported effects	The drug candidate lowers inflammation, fights resistant bacteria, and speeds up tissue repair.
Definition of phytopharmaceutical drug	A phytopharmaceutical drug is a purified and standardized fraction of a medicinal plant extract containing a minimum of 4 bioactive compounds.
Regulatory readiness	The research provides a comprehensive Investigational New Drug (IND)-ready data package for the standardised botanical therapeutic.
Mission phase period	CSIR Phytopharmaceutical Mission Phase III applies to the period 2024-2027.
Mission translation function	CSIR Phytopharmaceutical Mission Phase III translates scientifically validated plant-based leads into modern, clinically useful therapeutic drugs.
Coordination	It is coordinated by CSIR-IIIM and labs like CSIR-IIC.
Mission focus areas	It focuses on creating IND-ready data packages, captive medicinal plant cultivation, and industry tech transfers.
Core goals	The mission mandates: developing phytopharmaceuticals for unmet medical needs through pre-clinical and clinical trials; scaling up medicinal plant cultivation and quality planting material production for a reliable raw-drug supply; linking farmers with industry to reduce import dependence and boost global market competitiveness.